

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

May 15, 2015

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalal Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopalkrishnan

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Dear Sir


Re.: Press Release

We are forwarding you herewith copy of press release proposed to be published in the newspapers in the matter of audited financial results for the quarter and year ended on March 31, 2015 the same may please receive in order.

Thanking you

Yours faithfully

For **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above

Zydus Cadila's Net Profit soars to Rs. 1151 crore

Ahmedabad, May 15, 2015

Announcing the results for the year ended 31st March 2015, Zydus Cadila registered a Net Profit of Rs. 1151 crores, up by 43% from Rs. 804 crores. During the year, the company registered gross sales of Rs. 8658 crores, up by 20% from Rs. 7208 crores in the corresponding period last year, on a consolidated basis.

For the fourth quarter ended 31st March 2015, the group registered gross sales of Rs. 2297 crores, up by 18% from Rs. 1952 crores in the corresponding period last year on a consolidated basis. Net Profit for the same period stood at Rs. 350 crores. The Board of Directors of the Company in their meeting proposed a dividend of 240%.

During the year, the group launched Exemptia, the world's first biosimilar for Adalimumab which is the largest selling therapy worldwide. This biosimilar is a part of the group's robust biologics programme which has the largest number of monoclonal antibodies under development in India. Exemptia is marketed by Zydus Biovation and Zydus BioNext - new divisions launched exclusively to market this ground breaking therapy for inflammatory arthritis and Inflammatory Bowel Disease. During the year, the group also launched SoviHep, the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences.

Advancing its discovery research programme, the group has been exploring newer treatment options for its breakthrough drug Lipaglyn™ (Saroglitazar) and initiated Phase III trials of the molecule for patients suffering from lipodystrophy and nonalcoholic steatohepatitis (NASH), during the year. The group initiated Phase I clinical trials in the United States for ZYDPLA1, a novel, orally active, small molecule DPP-4 inhibitor to treat Type-2 Diabetes. Phase I clinical trials are also underway in Australia for its IND - ZYAN 1, a HIF-PH inhibitor for treating anemia.

Strengthening its regulatory pipeline, the group filed 38 ANDAs during the year with the US FDA, taking the cumulative filings to 260. The group received 8 ANDA approvals during the year taking the total to 99 product approvals.
